000			01942 a2200517 4500
005			20250515115539.0
264		0	_c20081014
008			200810s 0 0 eng d
022			_a0028-3908
024	7		_a10.1016/j.neuropharm.2008.03.005 _2doi
040			_aNLM _beng _cNLM
100	1		_aZhang, Xiaoqun
245	0	0	_aNeurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease. _h[electronic resource]
260			_bNeuropharmacology _cJun 2008
300			_a1143-52 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntiparkinson Agents _xtherapeutic use
650	0	4	_aAutoradiography _xmethods
650	0	4	_aBehavior, Animal
650	0	4	_aCalcium-Calmodulin-Dependent Protein Kinase Type 2 _xmetabolism
650	0	4	_aCocaine _xanalogs & derivatives
650	0	4	_aDisease Models, Animal
650	0	4	_aDopamine _xmetabolism
650	0	4	_aFeedback _xphysiology
650	0	4	_aFunctional Laterality
650	0	4	_aGene Expression Regulation _xdrug effects
650	0	4	_aLevodopa _xtherapeutic use
650	0	4	_aOxidopamine _xtoxicity
650	0	4	_aParkinson Disease _xdrug therapy
650	0	4	_aPeptide Fragments _xpharmacokinetics
650	0	4	_aQuinolines _xpharmacology
650	0	4	_aRadioisotopes _xpharmacokinetics
650	0	4	_aRats
650	0	4	_aRats, Sprague-Dawley
650	0	4	_aReceptors, Neurokinin-3 _xphysiology
650	0	4	_aSerine _xmetabolism
650	0	4	_aSubstance P _xanalogs & derivatives
650	0	4	_aSympatholytics _xtoxicity
650	0	4	_aTyrosine 3-Monooxygenase _xmetabolism
700	1		_aAndren, Per E
700	1		_aChergui, Karima
700	1		_aSvenningsson, Per
773	0		_tNeuropharmacology _gvol. 54 _gno. 7 _gp. 1143-52
856	4	0	_uhttps://doi.org/10.1016/j.neuropharm.2008.03.005 _zAvailable from publisher's website
999			_c17921281 _d17921281